258 filings
Page 4 of 13
8-K
3g0uw2z 1kg9
4 Nov 21
GBT Reports Third Quarter 2021 Financial Results
4:09pm
8-K
sdrvjg
4 Nov 21
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
9:06am
8-K
7nnpzx1z1uz sayer
7 Sep 21
Other Events
8:02am
8-K
vybkxc1 b674ky5s4
3 Aug 21
GBT Reports Second Quarter 2021 Financial Results
4:07pm
8-K
kiu1o16i dj03
22 Jul 21
Submits Supplemental New Drug Application to the U.S. FDA for Oxbryta® (voxelotor) in Children with SCD Ages 4 to 11
7:01am
8-K
fzwrdjd7ooosjb
17 Jun 21
Submission of Matters to a Vote of Security Holders
5:28pm
8-K
61qyl oxt
14 Jun 21
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
7:01am
8-K
2ensge5hb4aeny6iidiq
11 Jun 21
Analysis from Phase 2a HOPE-KIDS 1 Study Featured in Oral Presentation
6:05am
8-K
efdww2a zq9hu2t
12 May 21
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
10:01am
8-K
x9iilhk539k z7
5 May 21
GBT Reports First Quarter 2021 Financial Results
4:10pm
DEFA14A
h2w7h
28 Apr 21
Additional proxy soliciting materials
4:04pm
DEFA14A
yuc4w98m4k
28 Apr 21
Additional proxy soliciting materials
4:03pm
8-K
z0dgf
18 Mar 21
Departure of Directors or Certain Officers
7:05am
8-K
nrkex8afpuv0c0wrx
16 Mar 21
Entry into a Material Definitive Agreement
7:00am
8-K
lppvrnr7rxipcctqg7o
24 Feb 21
GBT Reports Recent Business Progress and Fourth Quarter and Full Year 2020 Financial Results
4:05pm
8-K
vjmwbuyh4p
4 Feb 21
GBT Initiates Expanded Access Protocol for Oxbryta® (voxelotor) in Pediatric Patients with Sickle Cell Disease in the United States
8:00am